Key regions: China, Europe, Australia, United States, Germany
The Other Pharmaceuticals market in Southern Asia has been experiencing significant growth in recent years.
Customer preferences: Customers in Southern Asia have shown a growing preference for alternative medicines and treatments, leading to an increase in demand for Other Pharmaceuticals. Additionally, the region's aging population has also contributed to the growth of this market.
Trends in the market: India, one of the largest markets in Southern Asia, has been driving the growth of the Other Pharmaceuticals market in the region. The country has a large population that is increasingly seeking alternative treatments, leading to a surge in demand for these products. Furthermore, the Indian government has been promoting the use of alternative medicines, providing further support for the growth of this market.In Pakistan, the Other Pharmaceuticals market has also been growing steadily. This is due to the increasing awareness of alternative treatments and the growing popularity of traditional medicines such as Ayurveda and Unani. In addition, the government has been promoting the use of alternative medicines, providing further support for the growth of this market.
Local special circumstances: In Bangladesh, the Other Pharmaceuticals market has been growing due to the country's large population and the high prevalence of chronic diseases. The government has also been promoting the use of alternative medicines, which has further supported the growth of this market.In Sri Lanka, the Other Pharmaceuticals market has been growing due to the country's large aging population and the increasing prevalence of chronic diseases. Additionally, the government has been promoting the use of alternative medicines, which has further supported the growth of this market.
Underlying macroeconomic factors: The growth of the Other Pharmaceuticals market in Southern Asia can also be attributed to the region's strong economic growth and increasing disposable income. As people become wealthier, they are more likely to spend money on healthcare and alternative treatments. Furthermore, the region's large population provides a significant customer base for the market to grow.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
